logo-loader
RNS
viewArix Bioscience PLC

Arix Bioscience Plc - Aura announces updated Phase 1b/2 clinical data

Arix Bioscience plc

Aura announces updated Phase 1b/2 clinical data

(“Arix”, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company, Aura Biosciences (“Aura”), presented updated clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, Aura’s lead product candidate for the first line treatment of primary choroidal melanoma, at the 43rd Annual Macula Society Meeting in The updated data demonstrate that multiple administrations of light-activated AU-011 were well-tolerated. Tumour control and vision preservation data continue to be supportive of the planned Phase 3 registration trial in the second half of 2020. , :LONDON24 February 2020Arix Bioscience plcSan Diego, CA.

The full announcement can be accessed on Aura’s website at: and full text of the announcement from Aura is contained below.http://www.aurabiosciences.com/news-and-publications

ENDS

Enquiries

For more information on Arix, please contact:

, Head of Investor Relations +44 (0)20 7290 1072  Arix Bioscience plc


Charlotte Parry[email protected]

Mary Clark, +44 (0)203 950 9144Optimum Strategic Communications


Supriya Mathur[email protected]

AboutArix Bioscience plc

is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.Arix Bioscience plc

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

www.arixbioscience.com

Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the 43 Annual Macula Society Meetingrd

Light-Activated AU-011 Holds Significant Potential as a First Line Treatment for Choroidal Melanoma

– Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tumors such as ocular and bladder cancers, today announced the presentation of updated clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the first line treatment of primary choroidal melanoma, at the 43 Annual Macula Society Meeting, which took place inCAMBRIDGE, MAFebruary 24, 2020rdFebruary 19-22, 2020San Diego, CA.

“The Phase 1b/2 data being recognized at the meeting this year show that AU-011 continues to be well tolerated, with a statistically significant reduction in tumor growth rate and vision preservation,” said , M.D., and of .Macular SocietyWeill Cornell Medical CollegeRetina ConsultantsAmy C. ScheflerHouston

“The high tumor control rates observed to date, together with the high rate of vision preservation, including in patients at high risk for vision loss with sub-macular and peripapillary tumors continue to support AU-011’s significant potential to change the treatment paradigm for patients battling choroidal melanoma,” said , MD, Chief Medical Officer and Head of Research and Development of Aura Biosciences.  “I am proud of the work the company has done to make a significant progress in this ultra-rare disease.”Cadmus Rich

Updated Results from the Phase 1b/2 Study Evaluating AU-011 

gave an oral presentation titled, “Study Update of an Ongoing Phase 1b/2 Open-label Clinical Trial of AU-011 for the Treatment of Small to Medium Choroidal Melanoma,” which highlighted updated data from the ongoing open-label Phase 1b/2 clinical trial, and described the design of the planned Phase 3 trial that Aura expects to initiate during the second half of 2020.Dr. Schefler

The updated data demonstrate that multiple administrations of light-activated AU-011 were well-tolerated.  Among the patients evaluated for safety (n=52), the most common treatment-related adverse events (AEs) were expected and included anterior chamber inflammation, posterior chamber inflammation and increase in intraocular pressure; all were manageable with standard-of-care treatments and the majority resolved without clinical sequelae.  Notably, the posterior inflammation appears to originate within and/or around the tumor which is consistent with AU-011’s mechanism of action of acute tumor necrosis.  There were two treatment-related serious AEs (vision loss; 3.6%). Tumor control and vision preservation data continue to be supportive of the planned Phase 3 registration trial.  

About Choroidal Melanoma

Choroidal melanoma is a rare and aggressive type of eye cancer. Choroidal melanoma is the most common primary intraocular tumor in adults and develops in the uveal tract of the eye. No targeted therapies are available at present, and current radiotherapy treatments can be associated with severe visual loss and other long-term sequelae such as dry eye, glaucoma, cataracts and radiation retinopathy. The most common current treatment is plaque radiotherapy, which involves surgical placement of a radiation device on the exterior of the eye over the tumor. The alternative is enucleation, or total surgical removal of the eye. Choroidal melanoma metastasizes in approximately 50 percent of cases with liver involvement in 80-90% of cases and, unfortunately, metastatic disease is universally fatal (source: OMF). There is a very high unmet need for a new vision sparing targeted therapy that could enable early treatment intervention for this life-threatening rare disease given the lack of approved therapies, and the comorbidities of radioactive treatment options.

About Light-Activated AU-011

AU-011 is a first-in-class targeted therapy in development for the treatment of primary choroidal melanoma. The therapy consists of proprietary viral-like particle bioconjugates (VPB) that are activated with an ophthalmic laser. The VPBs bind selectively to unique receptors on cancer cells in the eye and are derived from technology originally pioneered by Dr. of the at the (NCI), recipient of the 2017 Lasker-DeBakey Award. Upon activation with an ophthalmic laser, the drug rapidly and specifically disrupts the cell membrane of tumor cells while sparing key eye structures, which may allow for the potential of preserving patients’ vision and reducing other long-term complications of radiation treatment. AU-011 can be delivered using equipment commonly found in an ophthalmologist’s office and does not require a surgical procedure, pointing to a potentially less invasive, more convenient therapy for patients and physicians. AU-011 for the treatment of choroidal melanoma has been granted orphan drug and fast track designations by the and is currently in clinical development.John SchillerCenter for Cancer ResearchNational Cancer InstituteU.S. Food and Drug Administration

About Aura Biosciences

is a clinical-stage biopharmaceutical company developing a new class of oncology therapies based on a novel tumor targeting technology for initial application in primary tumors such as ocular and bladder cancers with the potential to treat other cancers.  The Company’s proprietary technology platform utilizes viral-like particle bioconjugates (VPBs) that have a dual selectivity mechanism with targeted binding to cancer cells, followed by activation using a common laser.  These potent cytotoxic therapies result in acute tumor cell necrosis, while sparing surrounding healthy tissue and activating the immune system to generate an anti-tumor response.  Aura’s lead product candidate belzupacap serotalocan (AU-011) is currently in Phase 2 development for the treatment of choroidal melanoma, a vision and life-threatening form of eye cancer for which there are currently no approved therapies.  In a Phase 1b/2 study, AU-011 demonstrated compelling efficacy, including high rates of tumor control and vision preservation, along with a favorable safety profile, in patients with choroidal melanoma.  The development of AU-011 is partially supported by funding awarded under a CRADA from the of Health’s .  Future pipeline applications for Aura’s technology include choroidal metastases and primary bladder carcinoma.  Aura is headquartered in , MA.  For more information, visit or follow us on .Aura Biosciences, Inc.U.S. National InstitutesNational Cancer InstituteCambridgewww.aurabiosciences.comTwitter

617.340.6075 |Investor and Media Contact:


Joseph RayneArgot Partners[email protected]

Quick facts: Arix Bioscience PLC

Price: 95.5

Market: LSE
Market Cap: £129.45 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE